menu
    • menu
    [{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Marubeni Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Antibiotic","year":"2025","type":"Acquisition","leadProduct":"Meropenem","moa":"PBP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.29999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma \/ Marubeni Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Marubeni Corporation"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xeruborbactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSP-1007","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitovant Biopharma \/ Sumitomo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sumitovant Biopharma \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ANT3310","moa":"||Serine-beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Antabio \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Bpifrance"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"INFEX Therapeutics","sponsor":"Venus Remedies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||MBL","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"INFEX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INFEX Therapeutics \/ Venus Remedies","highestDevelopmentStatusID":"5","companyTruncated":"INFEX Therapeutics \/ Venus Remedies"},{"orgOrder":0,"company":"Antabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ANT3310","moa":"||Serine-beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antabio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antabio \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Menarini","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Aceragen","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sodium Fusidate","moa":"||Bacterial protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aceragen \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Idera Pharmaceuticals"},{"orgOrder":0,"company":"Antabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ANT3310","moa":"||Serine-beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Meropenem, anhydrous

    Menu

    Meropenem, anhydrous

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sumitomo Pharma

                            Japan arrow
                            AGGSpend
                            Not Confirmed

                            Sumitomo Pharma

                            Japan arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meropenem

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Marubeni Corporation

                            Deal Size : $301.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Marubeni Acquires Sumitomo's Asia Pharma Unit in $480M Deal

                            Details : Through the acquisition, Marubeni will leverage the Sumitomo Asian approved products, which includes Meronem (meropenem trihydrate), indicated for Pneumonias.

                            Product Name : Meronem

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            April 02, 2025

                            Lead Product(s) : Meropenem

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Marubeni Corporation

                            Deal Size : $301.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            INFEX Therapeutics

                            United Kingdom arrow
                            AGGSpend
                            Not Confirmed

                            INFEX Therapeutics

                            United Kingdom arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MET-X,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Venus Remedies

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Venus Remedies Licenses MET-X from Infex for India Market

                            Details : The agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.

                            Product Name : MET-X

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            February 27, 2025

                            Lead Product(s) : MET-X,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Venus Remedies

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Antabio

                            France arrow
                            AGGSpend
                            Not Confirmed

                            Antabio

                            France arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antib...

                            Details : MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.

                            Product Name : ANT3310

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 25, 2023

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Qpex Biopharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Qpex Biopharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xeruborbactam,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Pro...

                            Details : ORAvance (Xeruborbactam) an orally-administered combination product that delivers xeruborbactam to treat infections that occur in outpatient and community setting caused by drug-resistant gram-negative bacteria.

                            Product Name : QPX7728

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 17, 2022

                            Lead Product(s) : Xeruborbactam,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sumitovant Biopharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Sumitovant Biopharma

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KSP-1007,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Sumitomo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem...

                            Details : It appears from nonclinical data that KSP-1007 broadly and strongly inhibits β-lactamases, which are enzymes that are produced by bacteria that can degrade carbapenem antibiotics. Sumitovant is leading the program of the compound in the U.S.

                            Product Name : KSP-1007

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 02, 2022

                            Lead Product(s) : KSP-1007,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Sumitomo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aceragen

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Aceragen

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Idera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Idera Pharmaceuticals Acquires Aceragen

                            Details : The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.

                            Product Name : ACG-701

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 28, 2022

                            Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Idera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Menarini

                            Italy arrow
                            AGGSpend
                            Not Confirmed

                            Menarini

                            Italy arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : $113.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Tr...

                            Details : Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue...

                            Product Name : Vaborem

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : SciClone Pharmaceuticals

                            Deal Size : $113.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Antabio

                            France arrow
                            AGGSpend
                            Not Confirmed

                            Antabio

                            France arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $10.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            French Multidisciplinary Consortium ARPEGE Awarded Public Funding of Close To €9 Million to Fight Antibiotic...

                            Details : The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.

                            Product Name : ANT3310

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 01, 2022

                            Lead Product(s) : ANT3310,Meropenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $10.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Theriva Biologics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Theriva Biologics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribaxamase,Meropenem

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (rib...

                            Details : SYN-004 (ribaxamase), is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within GI tract, thereby preventing antibiotic-mediated damage to the gut microbiome and reducing adverse outcomes associated with antibiotic-med...

                            Product Name : SYN-004

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 11, 2022

                            Lead Product(s) : Ribaxamase,Meropenem

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Melinta Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Melinta Therapeutics

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle...

                            Details : Under the terms of the deal, Hikma will responsible for the registration and commercialization of Orbactiv and Vabomere across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Ba...

                            Product Name : Vabomere

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            April 29, 2021

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth